top
Please input keywords
Order
*Country
United States
China
France
Germany
Netherlands
United Kingdom
Japan
South Korea
Israel
Australia
Hong Kong, China
New Zealand
Russia
Singapore
Taiwan, China
India
Aland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua & Barbuda
Argentina
Armenia
Aruba
Ascension Island
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
British Indian Ocean Territory
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Canary Islands
Cape Verde
Caribbean Netherlands
Cayman Islands
Central African Republic
Ceuta & Melilla
Chad
Chile
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo - Brazzaville
Congo - Kinshasa
Cook Islands
Costa Rica
Côte d’Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czechia
Denmark
Diego Garcia
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands
Faroe Islands
Fiji
Finland
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hungary
Iceland
Indonesia
Iran
Iraq
Ireland
Isle of Man
Italy
Jamaica
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau, China
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar (Burma)
Namibia
Nauru
Nepal
New Caledonia
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territories
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Islands
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Rwanda
Samoa
San Marino
São Tomé & Príncipe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia & South Sandwich Islands
South Sudan
Spain
Sri Lanka
St. Barthélemy
St. Helena
St. Kitts & Nevis
St. Lucia
St. Martin
St. Pierre & Miquelon
St. Vincent & Grenadines
Sudan
Suriname
Svalbard & Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Tajikistan
Tanzania
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad & Tobago
Tristan da Cunha
Tunisia
Turkey
Turkmenistan
Turks & Caicos Islands
Tuvalu
U.S. Outlying Islands
U.S. Virgin Islands
Uganda
Ukraine
United Arab Emirates
United Nations
Uruguay
Uzbekistan
Vanuatu
Vatican City
Venezuela
Vietnam
Wallis & Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-hTROP2 MC38 plus
Common name
B-hTROP2 MC38 plus Catalog number    311584
Aliases tumor associated calcium signal transducer 2, TACSTD2, EG Disease  Colon carcinoma
Organism
Mouse
Strain  C57BL/6
Tissue types Colon Tissue  Colon

Description


Expression cassettes containing the exogenous promoter and human TROP2 CDS were randomly inserted into the genome of B-hTROP2 MC38 plus cells. Human TROP2 was detected to be highly expressed on the surface of B-hTROP2 MC38 plus cells.

Application

B-hTROP2 MC38 plus cells can form tumors in vivo and can be used for efficacy studies.

Targeting strategy

Gene targeting strategy for B-hTROP2 MC38 plus cells. 
Expression cassettes containing the exogenous promoter and human TROP2 CDS were randomly inserted into the genome of MC38 cells that do not express the mouse TROP2 gene themselves.

Protein expression analysis 


Human TROP2 expression analysis in B-hTROP2 MC38 plus cells by flow cytometry. 
Single cell suspensions of wild-type MC38 and B-hTROP2 MC38 plus cultures were stained with species-specific anti-TROP2 antibody. Human TROP2 was detected on the surface of B-hTROP2 MC38 plus cells but not wild-type MC38 cells. The 3-B10 clone of B-hTROP2 MC38 plus cells was used for in vivo tumor growth assays.

Tumor growth curve & Body weight changes


Subcutaneous homograft tumor growth of B-hTROP2 MC38 plus cells. 

B-hTROP2 MC38 plus cells (5x105) and wild-type MC38 cells (5x105) were subcutaneously implanted into C57BL/6 mice (female, 7-week-old, n=5). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B)  Body weight (Mean±SEM). Volume was expressed in mm3 using the formula: V=0.5 X long diameter X short diameter2. As shown in panel A, B-hTROP2 MC38 plus cells were able to form tumors in vivo and can be used for efficacy studies.

Protein expression analysis of tumor cells

from clipboard


B-hTROP2 MC38 plus cells were subcutaneously transplanted into C57BL/6 mice (n=5), and on 28 days post inoculation, tumor cells were harvested and assessed for human TROP2 expression by flow cytometry. As shown, human TROP2 was highly expressed on the surface of tumor cells. Therefore, B-hTROP2 MC38 plus cells can be used for in vivo efficacy studies of TROP2 therapeutics.

Tumor growth curve & Body weight changes


from clipboard


Subcutaneous homograft tumor growth of B-hTROP2 MC38 plus cells. B-hTROP2 MC38 plus cells (5x105, 1x106, 5x106) and wild-type MC38 cells (5x105) were subcutaneously implanted into B-hCD3E mice (female, 7-week-old, n=6). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B)  Body weight (Mean ± SEM). Volume was expressed in mm3 using the formula: V=0.5 X long diameter X short diameter2. As shown in panel A, B-hTROP2 MC38 plus cells were able to establish tumors in vivo and can be used for efficacy studies.


from clipboard


Subcutaneous homograft tumor growth of B-hTROP2 MC38 plus cells. B-hTROP2 MC38 plus cells (5x105, 1x106, 5x106) and wild-type MC38 cells (5x105) were subcutaneously implanted into B-h4-1BB mice (female, 9-week-old, n=6). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B)  Body weight (Mean ± SEM). Volume was expressed in mm3 using the formula: V=0.5 X long diameter X short diameter2. As shown in panel A, B-hTROP2 MC38 plus cells were able to establish tumors in vivo and can be used for efficacy studies.


In vivo efficacy of anti-human TROP2 antibody conjugated TLR8 agonists

from clipboard


Antitumor activity of TROP2 antibody conjugated TLR8 agonists in B-hTLR8 mice.(A) Anti-human TROP2 antibody conjugated TLR8 agonists inhibited MC38 tumor growth in B-hTLR8 mice. Murine colon cancer B-hTROP2 MC38 cells were subcutaneously implanted into homozygous B-hTLR8 mice (female, 9 week-old, n=8). Mice were grouped according to body weight differences, at which time they were treated antibody conjugates with different doses. (B) Body weight changes during treatment. As shown in panel A, anti-human TROP2 antibody conjugated TLR8 agonists were efficacious in controlling tumor growth in B-hTLR8 mice, demonstrating that B-hTLR8 mouse model is a promising model for preclinical in vivo studies to evaluate antibodies conjugated TLR8 agonists. Values are expressed as mean ± SEM.